CLSA on Cadila Health: The brokerage maintained a 'buy' call on the stock and raised its target to Rs 440 per share from Rs 400 earlier. The company aims to cut debt by Rs 800-1000 crore in FY21, it added.
Morgan Stanley on Cadila Health: The brokerage maintained 'overweight' call on the stock with a target at Rs 300 per share. It added that Cadila Health’s earnings concentration is waning for the company but expects the company to finalise Ph3 clinical trial protocol for Saroglitazar.
CLSA on LIC Housing: The brokerage maintained a 'buy' call on the stock but cut its target to Rs 350 per share from Rs 530 earlier. Asset quality has been weak since H2FY19 and CLSA expects it to remain under pressure for the next 18 months.
CLSA on Ramco Cements: The brokerage maintained a 'sell' call on the stock but raised target to Rs 515 per share from Rs 480 earlier.
CLSA on IRB Infra: The brokerage maintained a 'buy' call on the stock with a target at Rs 166 per share. The company has bagged Mumbai-Pune e-way concession again for 10 years and expects the new concession awards by NHAI from Q2, the brokerage added.
Credit Suisse on PNB: The brokerage maintained 'underperform' rating on the stock and cut its target to Rs 29 from Rs 32 earlier. It added that standalone operating performance is better than expectations in the March quarter led by loan growth.